Addex Therapeutics Ltd

As of March 31, 2026, Addex Therapeutics Ltd carries a market capitalization of 6.32M, placing it among publicly traded companies globally. Its enterprise value stands at 5.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Addex Therapeutics Ltd's next confirmed earnings release is scheduled for November 9, 2026.

As of March 31, 2026, Addex Therapeutics Ltd has 119.32M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 198.78, and the price-to-book ratio stands at 1.92.

These figures are as of March 31, 2026. The EV/Sales ratio of 183.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.49M versus a market cap of 6.32M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Addex Therapeutics Ltd maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.11, indicating elevated leverage, while an interest coverage ratio of -943.50 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Addex Therapeutics Ltd posted a negative return on equity (ROE) of -120.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -97.83, reflecting losses generated across the asset base. The company generates approximately 11,988.80 in revenue per employee across its workforce of 2.50, a quick read on workforce productivity versus industry peers.

As of the close on October 1, 2026, Addex Therapeutics Ltd's stock has declined approximately 73.33% over the past 52 weeks.

Over the twelve months ended March 31, 2026, Addex Therapeutics Ltd generated 29,972.00 in revenue and converted that into -6.97M in net income, yielding earnings per share of -0.06. EBITDA reached -2.67M, while operating income came in at -2.69M.

As of March 31, 2026, Addex Therapeutics Ltd holds 937,500.00 in cash and equivalents against 102,269.00 in total debt, resulting in a net debt position of -935,153.00. Total book value stands at 3.29M, with working capital of -32,560.00 providing operational flexibility.

Addex Therapeutics Ltd produced -2.34M in operating cash flow over the twelve months ended March 31, 2026. After subtracting - - in capital expenditures, free cash flow totaled -2.34M - equivalent to -0.02 per share.

These figures cover the twelve months ended March 31, 2026. The operating margin of -8,968.91 and net profit margin of -23,245.44 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Addex Therapeutics Ltd paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -39.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.21, meaning Addex Therapeutics Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Addex Therapeutics Ltd has an Altman Z-Score of -105.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.